On Friday, UBS initiated coverage of Sight Sciences Inc. (NASDAQ: SGHT) stock, a medical device company specializing in ophthalmic and optometric products, with a Buy rating and a price target of $5.50. According to InvestingPro data, the stock currently trades at $3.70, with analyst targets ranging from $4.00 to $6.00.
Despite recent market volatility, the company maintains strong financial health with a current ratio of 10.18, indicating robust liquidity. The firm's coverage begins as Sight Sciences is poised to transition its growth strategy from its OMNI surgical solution for glaucoma to its TearCare Dry Eye solution.
The analyst from UBS highlighted that after a challenging second half of 2023 and into 2024, the year 2025 is expected to be a foundational building year for Sight Sciences. The focus is set to shift to the TearCare Dry Eye solution, which is designed to treat meibomian gland disease, a form of dry eye affecting over 11 million patients. This represents an addressable market of approximately $2.5 billion.
InvestingPro analysis reveals the company maintains an impressive gross profit margin of 85.11%, suggesting strong potential for profitability as it scales operations. Despite projections that SGHT will generate less than $5 million from TearCare in 2024, the analyst expects sales to increase to 10% of the company's total sales by 2026 and over 20% by 2030.
The UBS analyst anticipates that as Sight Sciences transitions TearCare from a cash-pay model to a reimbursed model, it will experience a significant ramp-up in sales. This shift is expected to drive double-digit sales growth and gross margin expansion that exceeds consensus estimates for 2026 and beyond. The analyst's estimates are approximately 100 basis points higher than consensus for the year 2026.
Moreover, with 1,000 surgeons already trained to use TearCare, the market is considered ready for significant adoption once insurance coverage wins are secured. The analyst sees potential for sales to surpass their already above-consensus estimates for 2026 and onward.
While InvestingPro data shows current revenue at $79.54 million, subscribers can access 8 additional key ProTips and comprehensive financial metrics in the Pro Research Report, offering deeper insights into the company's growth trajectory.
In addition to the potential of the TearCare Dry Eye solution, UBS also notes the competitive edge that Sight Sciences' OMNI product has within the approximately $5 billion standalone glaucoma Minimally Invasive Glaucoma Surgery (MIGS) market. The firm expects improved execution in this area to support the company's growth.
In other recent news, Sight Sciences, Inc. (NASDAQ:SGHT) reported a slight year-over-year revenue increase in its third-quarter earnings call, despite falling short of expectations. The company's third-quarter revenue rose 1% year-over-year to $20.2 million, with surgical glaucoma revenue accounting for $18.6 million. However, the company's surgical glaucoma revenue saw a sequential decrease of 8% and dry eye revenue declined by 4% to $1.5 million for the quarter.
On the brighter side, Sight Sciences has conducted over 200,000 OMNI and 60,000 TearCare procedures and is focused on expanding market access for TearCare in reimbursed interventional dry eye treatments. The company also appointed Dr. MK Raheja as Executive Vice President of Research and Development to advance their surgical glaucoma pipeline.
In response to commercial challenges, Sight Sciences plans to enhance sales performance and strategic positioning. The company is contesting the final 2025 Medicare payment rule, which did not grant device-intensive status to OMNI procedures. Despite current setbacks, Sight Sciences remains optimistic about growth in the surgical glaucoma and dry eye segments in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.